Tamoxifen resistance: EGFR expression in hormone receptor-positive and HER2 negative breast cancer

被引：0
|
作者：
Bae, S. Y. [1 ]
Nam, S. J. [1 ]
Lee, S. K. [1 ]
Kim, S. W. [1 ]
Lee, J. E. [1 ]
Yu, J. H. [1 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-09-36
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-36
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer
    Kaklamani, Virginia G.
    Cianfrocca, Mary
    Ciccone, Jennifer
    Kindy, Kelly
    Rademaker, Alfred
    Wiley, Elizabeth L.
    Gradishar, William
    O'Regan, Ruth M.
    BIOMARKERS, 2010, 15 (02) : 191 - 193
  • [2] Understanding Resistance to Tamoxifen in Hormone Receptor-Positive Breast Cancer
    Higgins, Michaela J.
    Stearns, Vered
    CLINICAL CHEMISTRY, 2009, 55 (08) : 1453 - 1455
  • [3] HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer
    Christian F. Singer
    Daphne Gschwantler-Kaulich
    Anneliese Fink-Retter
    Georg Pfeiler
    Ingrid Walter
    Gernot Hudelist
    Samir Helmy
    Anne-Catherine Spiess
    Wolfgang Lamm
    Ernst Kubista
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 807 - 813
  • [4] HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer
    Singer, Christian F.
    Gschwantler-Kaulich, Daphne
    Fink-Retter, Anneliese
    Pfeiler, Georg
    Walter, Ingrid
    Hudelist, Gernot
    Helmy, Samir
    Spiess, Anne-Catherine
    Lamm, Wolfgang
    Kubista, Ernst
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (06) : 807 - 813
  • [5] HER2 and hormone receptor-positive breast cancer—blocking the right target
    Javier Cortés
    Cristina Saura
    Meritxell Bellet
    Eva Muñoz-Couselo
    Natalia Ramírez-Merino
    Virginia Calvo
    Jose Pérez
    María Vidal
    Nature Reviews Clinical Oncology, 2011, 8 : 307 - 311
  • [6] Benefits of capecitabine in hormone receptor-positive compared to hormone receptor-negative HER2 normal metastatic breast cancer
    Altundag, Kadri
    MEDICAL ONCOLOGY, 2024, 41 (06)
  • [7] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [8] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Irfan Cicin
    Hakan Karagol
    Ufuk Usta
    Atakan Sezer
    Sernaz Uzunoglu
    Rusen Alas-Cosar
    Tarkan Yetisyigit
    Kazim Uygun
    Medical Oncology, 2009, 26 : 335 - 343
  • [9] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Cicin, Irfan
    Karagol, Hakan
    Usta, Ufuk
    Sezer, Atakan
    Uzunoglu, Sernaz
    Alas-Cosar, Rusen
    Yetisyigit, Tarkan
    Uygun, Kazim
    MEDICAL ONCOLOGY, 2009, 26 (03) : 335 - 343
  • [10] Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015
    Vanacker, Helene
    Bally, Olivia
    Kassem, Loay
    Tredan, Olivier
    Heudel, Pierre
    Bachelot, Thomas
    BULLETIN DU CANCER, 2015, 102 (06) : S47 - S52
12345